<DOC>
	<DOC>NCT01766336</DOC>
	<brief_summary>To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.</brief_summary>
	<brief_title>A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>Complete Week 12 visit of AG201 Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests Is currently using any other investigational or experimental drugs or devices Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Agitation</keyword>
	<keyword>Aggression</keyword>
	<keyword>AD patients</keyword>
</DOC>